AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)

SAN FRANCISCO: Google said Friday it was banning online ads for unproven medical treatments including most stem cell and gene therapy.

"This new policy will prohibit ads selling treatments that have no established biomedical or scientific basis," Google policy adviser Adrienne Biddings said in a blog post.

Biddings said Google will "prohibit advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy and gene therapy."

Google will also ban "treatments that are rooted in basic scientific findings and preliminary clinical experience, but currently have insufficient formal clinical testing to justify widespread clinical use," she added.

The online giant said it made the decision due to "a rise in bad actors attempting to take advantage of individuals by offering untested, deceptive treatments."

The company said this was not an effort to diminish the importance of medical discoveries but maintained that "monitored, regulated clinical trials are the most reliable way to test and prove important medical advances."

Google said it took the action after consulting experts in the field and that its move was endorsed by the president of the International Society for Stem Cell Research, Deepak Srivastava.

In Google's statement, Srivastava was quoted as saying, "The premature marketing and commercialization of unproven stem cell products threatens public health, their confidence in biomedical research, and undermines the development of legitimate new therapies."

Online services have struggled to filter out misleading and deceptive content, including medical hoaxes, while remaining open platforms.

Earlier this year Facebook and Google-owned YouTube moved to reduce the spread of misleading health care claims after a media report showed the proliferation of bogus cancer cures on social media.

Facebook said it made changes as part of efforts to reduce the spread of misleading medical claims including from groups opposing the use of recommended vaccines.

A Wall Street Journal report, based on interviews with doctors, lawyers, privacy experts and others, found numerous false or misleading claims about cancer therapies online.

These included videos advocating the use of potentially dangerous cell-killing ointments, unverified dietary regimes, or unapproved  screening techniques.

 

Comments

Comments are closed.